The Pointerra Ltd (ASX: 3DP) share price is slumping heavily today. This comes after the 3D geospatial data technology company provided an update on its enterprise sales activity during the June quarter.

At the time of writing, Pointerra shares are down a sizeable 7.89% to 43.7 cents. In comparison, the All Ordinaries Index (ASX: XAO) is up 0.42% to 7,682 points.

How is Pointerra performing for the June quarter?

Investors are heading for the hills, selling Pointerra shares despite the company reporting growth across key sectors. A possible catalyst for the Pointerra share price could be that the result did not meet the market’s lofty expectations.

For the period ending 29 July 2021, Pointerra advised annual contract value (ACV) increased by US$91 million from 29 April. The 24% quarterly growth brings total ACV for Q4 FY21 to US$9.80 million.

Pointerra attributed the uplift in ACV to an increase in customers across a broad range of sectors in the United States and Australian markets. This included areas such as utilities, surveying and mapping, engineering, mining, as well as oil and gas.

In addition, the company observed a surge in spending for its suite of Software-as-a-Service (SaaS) services. The adoption of cloud asset management platforms jumped as a result of Pointerra continually developing its 3D geospatial data technology.

Just last month, the company acquired United States digital asset management business, Airovant. In 2020, ACV growth had come primarily from the United States utilities and mapping sectors. However, management noted the past couple of quarters has seen a broader take-up of its services.

The company lastly said that quarter-on-quarter cash receipts could change as new customers are onboarded with different payment cycles.

About the Pointerra share price

Looking at the last 12 months, Pointerra shares have generated a 130% gain for shareholders, but have fallen 10% year-to-date. The company’s share price is sitting just lower than the middle of its 52-week range of 17 cents to 92.5 cents.

Pointerra commands a market capitalisation of about $298 million, and has more than 677 million shares on its books.

The post What’s happening with the Pointerra (ASX:3DP) share price today? appeared first on The Motley Fool Australia.

More reading

• 3 growing small cap ASX shares to watch closely
• Here are the 5 best performing ASX tech shares from FY21

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pointerra Limited. The Motley Fool Australia has recommended Pointerra Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3zRoi4J

The Afterpay Ltd (ASX: APT) share price is finally catching a break on Thursday, bouncing 3.49% higher to $102.46.

Two weeks on from the Apple announcement

It’s been a little over two weeks since the headlines that Apple was developing its own BNPL service.

However, the selling pressure continues to linger, with the Afterpay share price tumbling 3.60% to $99 on Wednesday.

The Wednesday decline was off the back of above average trading volume, with almost 1.5 million shares changing hands compared to Afterpay’s 10-day average of approximately 1.05 million shares.

What’s driving the Afterpay share price on Thursday

Afterpay shares might be taking Wall Street’s lead after the Nasdaq Composite posted a solid 0.70% gain overnight.

The tech-heavy Nasdaq managed to run higher despite the Dow Jones Industrial Average and S&P 500 edging 0.36% and 0.02% lower respectively.

Encouraging, Afterpay’s major US competitor, Affirm Holdings Inc (NASDAQ: AFRM) managed to post a 2.82% gain to US$61.18 as well.

The broader BNPL sector is also bouncing higher on Thursday, with the large cap players taking charge.

The Zip Co Ltd (ASX: Z1P) share price is up 5.49% to $6.91.

While Sezzle Inc (ASX: SZL) is also posting a 2.39% gain to $8.15.

Smaller players including Openpay Group Ltd (ASX: OPY) and Laybuy Holdings Ltd (ASX: LBY) are trading a respective 6.22% and 1.14% higher.

Despite a small victory today, the Afterpay share price is still down 4.05% this week and down 13.96% year-to-date.

The post Why the Afterpay (ASX:APT) share price is in the green today appeared first on The Motley Fool Australia.

More reading

• Here’s why the Zip Co (ASX:Z1P) share price is leaping 5% today
• PayPal (NASDAQ:PYPL) share price falls on profit decline
• Why Afterpay, Nickel Mines, Nitro, & St Barbara shares are sinking
• Down 7% this week, why the Zip (ASX:Z1P) share price keeps falling
• The Afterpay (ASX:APT) share price is down 16% in a month. Here’s why

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3lbYNa3

The Crown Resorts Ltd (ASX: CWN) share price is in the red today after the company’s former director criticised its current chair.

According to former director John Poynton, Crown’s chair Helen Coonan, along with NSW Independent Liquor and Gambling Authority (ILGA) chair Philip Crawford attempted to wrongly axe his position on the board.

Right now, the Crown share price is $8.74 – 1.02% lower than its closing price yesterday.

Let’s take a closer look at Poynton’s criticisms.

Poynton speaks out

The Crown share price is falling after Poynton spoke to the Perth Casino Royal Commission yesterday.

Poynter told the commission Coonan and Crawford forced him to leave Crown’s board. He claims the 2 forced him to resign despite Commissioner Patricia Bergin having no issue with his position.

Poynton left Crown’s board on March 1 2021 due to his previous ties with James Packer’s Consolidated Press Holdings (CPH). The Crown board was concerned Poynton’s former position risked the Crown board’s independence.

Poynton said:

I was placed in a position where both the chair of the company and Mr Crawford were suggesting that my staying on the board would mean that the licence [from ILGA] would not be granted and in one stage I was given two hours’ notice to quit the board.

I got off the board because I thought at the time it was in the best interests of the company if the company was not going to be given a licence by ILGA and Mr Crawford.

Some six months later, the company still doesn’t have a licence. Therefore, I respectfully put that me being on the board would have nothing to do with that.

Poynton also claimed he was subject to a media campaign that was “based, in [his] view, on a false premise”. He said:

There was nothing in probity in NSW to say that someone couldn’t be on the board of a casino company merely because of a previous association with Mr Packer.

In Poynton’s witness statement, he said he was willing to step down if Crawford would confirm his resignation was only due to his previous ties with CPH. Poynton believed this would have helped protect his reputation.

However, Crawford and Coonan refused. Poynton said:

There were subsequent further threats made by both Mr Crawford and Ms Coonan that led me to have an untenable position.

Those interested can find the full, unedited transcript of Poynton’s appearance at the hearing here.

Crown share price snapshot

This year hasn’t been good for the Crown share price.

It has fallen 11% year to date. It is also 3% lower than it was this time last year.

The post Crown (ASX:CWN) share price slumps amid accusations against chair appeared first on The Motley Fool Australia.

More reading

• Here’s why the Crown Resorts (ASX:CWN) share price is in focus today
• Crown (ASX:CWN) share price drops following scathing written submission
• ASX 200 Weekly Wrap: Just like that… ASX back to record highs
• These were the worst performing ASX 200 shares last week
• ASX 200 edges higher, Crown falls, Pointsbet rises

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/378cjn2

The PointsBet Holdings Ltd (ASX: PBH) share price is missing out on the market’s gains on Thursday.

This is because the sports betting company requested a trading halt prior to the market open.

Why is the PointsBet share price halted?

The PointsBet share price was placed in a trading halt this morning so the company could launch an underwritten capital raising.

According to the release, PointsBet is aiming to raise approximately $400 million. This comprises a fully underwritten 1 for 9 accelerated pro rata renounceable entitlement offer, with retail rights trading, to raise approximately $184.9 million at $8.00 per new share, and a fully underwritten institutional placement to raise $215.1 million at $10.00 per new share.

With the PointsBet share price last trading at $11.29, this means discounts of 29.1% and 11.4%, respectively.

Why is PointsBet raising funds?

Given that PointsBet just finished FY 2021 (Q4 update here) with a cash balance of $245.5 million, investors may be curious why it is raising funds at this point.

According to the release, the company is raising funds to support its objective of consolidating and expanding upon its strong position in the rapidly expanding US sports betting and iGaming market.

Funding will be used to support North American marketing and client acquisition, technology and product development, US market access and government licensing fees, and continued investment in talent and scale of operations. Management also notes it will give it balance sheet flexibility.

PointsBet’s Managing Director and Group CEO, Sam Swanell, commented: “Since inception, PointsBet’s Board and management have been working to establish and consolidate the key building blocks that have put us in the strong position we are today to pursue the expansion of the North American sports betting and iGaming opportunity.”

“Today, in addition to our profitable Australian business, we have live operations in 6 US States with iGaming live in two of these states. By December 2022 we plan to be live in at least 19 North American states or provinces. The North American sports betting and iGaming market could be a US$54bn revenue opportunity by 2033 and our strategy is to continue to invest to become a top 5 player in this market, targeting a 10% market share in all key North American jurisdictions. The Capital Raising will position PointsBet to execute this strategy,” he concluded.

Co-Founders sell-down

PointsBet Co-Founders, Andrew and Nicholas Fahey and Sam Swanell, will be selling down some of their holding.

Nick and Andrew Fahey will be selling 2 million shares and Sam Swanell will be offloading 0.9 million shares at $10.00 per share. This represents 15% of their respective interests in PointsBet.

And while Mr Swanell has confirmed that he does not intend to sell any further shares for a period of 12 months, the Faheys haven’t made the same commitment.

Some of these shares will be bought by the company’s Chairman, Brett Paton. He has agreed to purchase 1.45 million of the shares being sold by the Co-Founders at $10.00 per share. The remainder of the shares will be placed at the placement price with an institutional investor, independent of the capital raising.

The PointsBet share price is up 116% over the last 12 months.

The post Why is PointsBet (ASX:PBH) raising $400 million? appeared first on The Motley Fool Australia.

More reading

• PointsBet (ASX:PBH) share price halted after Q4 update
• 3 stellar ASX growth shares rated as buys
• 3 stellar ASX growth shares that could be buys in August
• ASX 200 edges higher, Crown falls, Pointsbet rises
• Here’s why the PointsBet (ASX:PBH) share price is on the rise

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pointsbet Holdings Ltd. The Motley Fool Australia has recommended Pointsbet Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3f9On7b

The Oneview Healthcare PLC (ASX: ONE) share price is in the green today. Shares in the healthcare company received a boost after Oneview released its quarterly report earlier today.

At the time of writing, Oneview shares are up 2.27% to 45 cents.

Let’s take a look at how Oneview performed in the second quarter of 2021.

Oneview share price rises on quarterly report

Earlier today, Oneview released its report for the second quarter ending 30 June 2021.

The company’s financial performance was highlighted by a 42% increase on the previous corresponding period (pcp) in net operating cash outflows to €1.24 million ($2 million). This included €1.98 million ($3.18 million) in receipts from customers, a 56% increase on the pcp.

Despite a growing cash outflow, Oneview reported increased administrative and marketing costs for the quarter.

The company also noted a stable balance sheet, with a cash balance of €5.0 million ($8.03 million) as at 30 June 2021.

Oneview reports strong operational highlights

In addition to the company’s financial performance for the quarter, Oneview also elaborated on its operational achievements.

In particular, Oneview highlighted the company’s 5-year contract extension with its largest customer in Australia, Epworth HealthCare. Oneview also noted its 5-year contract with Northern Health in Melbourne.

Oneview also said it continues to work with its new partner Samsung. Early feedback from their combined market strategy has shown a preference for Cloud Enterprise vs. Cloud Star.

The second quarter of 2021 marked the first quarter of sales and marketing for Oneview’s Cloud Enterprise product. The company’s management was pleased with the market response and foreshadows a material increases in its sales pipeline.

Snapshot of the Oneview share price

Oneview is an Irish healthcare technology company that provides digital tools for patients and their caregivers.

Facilities systems and services are unified on Oneview’s Care Experience Platform with the aim of improving the overall care experience.

The company currently services 63 hospitals, operating in the US, Australia, the Middle East, and Asia.

The Oneview share price has had a stellar year thus far. Shares in the healthcare technology company have surged more than 948% since the start of the year.

The post Here’s why the Oneview (ASX:ONE) share price is climbing today appeared first on The Motley Fool Australia.

More reading

• Here’s why the Zip Co (ASX:Z1P) share price is leaping 5% today
• Own CSL (ASX:CSL) shares? Here’s what to look for this reporting season
• Capital keeps flowing into ASX Biotech shares in 2021
• Ramelius (ASX:RMS) share price lifts on record production
• CV Check (ASX:CV1) share price rockets 9% on business update

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3BKryAu

The S&P/ASX 200 Index (ASX: XJO) is having a pretty decent day on the markets this Thursday. At the time of writing, the ASX 200 is up a robust 0.37% to 7,407 points. But one ASX 200 share that’s doing a few better is the Zip Co Ltd (ASX: Z1P) share price.

Zip shares are currently up a healthy 4.57% to $6.86 a share, after closing at $$6.56 yesterday afternoon and opening at $6.65 a share this morning.

Like its typical pattern of late, Zip has had a wild week. Even though the company is up more than 5% today, Zip shares are still down almost 3% over the past 5 trading days, and down more than 10% over the past month.

The entire buy now, pay later (BNPL) sector was rocked by news earlier this month that both Apple Inc (NASDAQ: AAPL) and PayPal Holdings Inc (NASDAQ: PYPL) would be expanding their BNPL products.

In Apple’s case, it was a rumour that the electronics giant would be introducing a BNPL version of its popular Apple Pay service in ‘Apple Pay Later’. In PayPal’s case, it was the news that the company would be abolishing late fees on its own BNPL ‘Pay in 4’ service.

This news (which came out on the same day) really spooked BNPL investors, and the Zip share price (along with other ASX BNPL shares) has struggled ever since.

So what’s going on with this BNPL ASX share today?

Zip shares zip higher

Well, it’s not immediately obvious what has lit a rocket under Zip shares today, thus far. There have been no major news or announcements out of the company since 22 July, when Zip delivered its quarterly results report.

However, there is an obvious pattern today which Zip is clearly a part of. Most ASX BNPL shares are enjoying very healthy gains this Thursday. Take Zip’s arch-rival Afterpay Ltd (ASX: APT). Afterpay shares are currently up 3.4% to $102.35 a share. Sezzle Inc (ASX: SZL), Openpay Group Ltd (ASX: OPY) and Splitit Ltd (ASX: SPT) are also performing very well today.

The US BNPL company Affirm Holdings Inc (NASDAQ: AFRM) was also up big last night in US trading hours. Affirm shares rose a very enthusiastic 2.82% to finish the trading day at US$61.18 a share. Perhaps ASX investors have taken a lead from our American counterparts, and seen fit to pick up BNPL shares for relatively cheap prices today.

At the current Zip share price, the company has a market capitalisation of $3.68 billion.

The post Here’s why the Zip Co (ASX:Z1P) share price is leaping 5% today appeared first on The Motley Fool Australia.

More reading

• Has the record breaking Rio Tinto (ASX:RIO) share price hit its peak?
• ASX 200 midday update: Rio Tinto charges higher, IRESS rockets, Macquarie update
• Yes, share markets are high. But don’t sell
• 5 things to watch on the ASX 200 on Thursday
• ASX 200 drops, Spark jumps, Nickel Mines sinks

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO, Affirm Holdings, Inc., Apple, PayPal Holdings, and ZIPCOLTD FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2022 $75 calls on PayPal Holdings, long March 2023 $120 calls on Apple, and short March 2023 $130 calls on Apple. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia has recommended Apple and PayPal Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3f9pNDf

The CSL Limited (ASX: CSL) share price has struggled to deliver shareholder value in 2021, with a year-to-date return of about 2.05%.

With August reporting season on the horizon, what should investors look out for in the company’s results?

All eyes on plasma collections

In CSL’s annual report to shareholders, it said “at the origins of our value chain, plasma donors fuel our pipeline …”.

Plasma collections form the backbone of many CSL treatments including its immunoglobulins business, which contributed approximately 43% of the group’s 1H21 revenue.

The last time CSL updated the market on its plasma collections was February, when the company released its FY21 half-year results.

It advised “plasma collections adversely impacted by COVID-19” and that collection volumes in December 2020 were roughly 80% of the December 2019 volumes.

The company launched multiple initiatives in an attempt to drive plasma collection figures. This included enhanced targeted marketing, improving the donor experience and the rollout of 29 new collection centres in FY21.

The CSL share price will be put to the test as to whether or not these initiatives are paying dividends.

CSL competitor notes recovery in plasma collections

The Motley Fool has previously covered observations of a plasma donation recovery in the United States.

Grifols, a US$14 billion Spanish multinational biotech company has observed some improvements in the plasma collections space.

In the company’s quarterly results on 4 May, it said, “In the United States, plasma donations are gradually recovering. Of note was the trend observed in January, February and April in the wake of the country’s vaccination rollouts and the easing of COVID-19 restrictions, while taking into account the mitigating effect of stimulus incentives issued in March and December.”

CSL share price tumbles on seemingly good results in February

It can be difficult to get a read on how the CSL share price will perform after the release of its full-year results on 18 August.

Looking back, the company delivered seemingly positive half-year results on 18 February with a 15% increase in revenue to US$4,911 million and a 44% jump in net profit after tax (NPAT) to US$1,248 million.

CSL acknowledged that COVID-19 had “tempered the performance of CSL Behring whilst boosting the performance of Seqirus”.

The company reaffirmed its (NPAT) guidance of US$2,170 million to US$2,265 million for FY21, which represents an increase of 3.2% to 7.7% on FY20 figures.

The CSL share price closed at $289.00 on 18 February and tumbled from there. It hit a year-to-date low of $246.00 on 8 March. The shares have since rallied to a year-to-date peak of $305.52, which it reached on 18 June.

At the time of writing today, the CSL share price is $290.53, up 1.94%.

The post Own CSL (ASX:CSL) shares? Here’s what to look for this reporting season appeared first on The Motley Fool Australia.

More reading

• Why the CSL (ASX:CSL) share price is up 5% in a week
• 6 ASX shares to rocket when COVID Delta passes
• ASX 200 Weekly Wrap: Just like that… ASX back to record highs
• 3 reasons why the CSL (ASX:CSL) share price could be one to look at
• 3 ASX 50 shares named as buys

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3l3PZ6d

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date.

Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain, one observes that this total increases to over $1 billion, according to today’s Australian Financial Review.

Here, we examine just what is driving this recent trend in capital inflows towards ASX Biotech shares.

What is behind the surge in inflows to ASX Biotech shares this year?

There has been a spate of capital raised for ASX Biotech shares this year, such as Imugene Limited (ASX: IMU), Immutep Ltd (ASX: IMM) and Aroa Biosurgery Ltd (ASX: ARX).

For instance, Imugene recently “completed an upsized $95 million offer”, issuing ~300 million additional shares at a price of 30 cents apiece.

Aroa also “banked $53 million in a placement and share purchase plan [SPP]” earlier this week to eligible investors at $1.165 per share. $5 million of this total is sought from the SPP.

There appears to be “four big reasons behind the recent flurry of [capital] raising” trends that have occurred this year.

These include the establishment of new equity-focused healthcare investment funds, outsized returns in the broad sector, and a cluster of collaborations with big pharmaceutical companies.

Moreover, it also appears the biotech sector “has the flavour of the month for investors”, as per the Financial Review.

Bell Potter Securities analyst Darren Craike was quoted saying:

A lot of generalist funds are looking for alpha [above market return] in their portfolios…so many have started to gravitate to healthcare where there have been some exceptional returns in the last two to three years.

Moreover, the trends look set to continue for the time being, with a number of pre-IPO’s on the cards.

To illustrate, Tissue Repair which is a regenerative medicine and aesthetic dermatology company, plans on “targeting a $25 million raise” via listing this year.

Additionally, upcoming biotech names Triad Lifesciences and Vitfrafy Lifesciences “are also confirmed to be pursuing listings” this year.

ASX Biotech shares snapshot

The basket of ASX Biotech shares contained within the S&P / ASX 200 Index (ASX: XJO) has provided a return of 116% since March of this year.

This select group has outpaced the overall broad index, which has posted a return of ~12.5% this year to date.

Such returns help to explain the attractiveness of ASX Biotech shares for Australian investors at the current standing.

The post Capital keeps flowing into ASX Biotech shares in 2021 appeared first on The Motley Fool Australia.

More reading

• Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
• The 5 best ASX shares of FY21 revealed
• The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
• 3 ASX healthcare shares with big news coming
• How these top ASX biotech shares performed in FY21

from The Motley Fool Australia https://ift.tt/2UZRYh9

The Ramelius Resources Limited (ASX: RMS) share price is trading higher on Thursday. This comes after the company released its June quarterly and full-year FY21 activities report.

At the time of writing, shares in the gold mining company are up 2.17% to $1.65.

What did Ramelius announce?

Investors are bidding the Ramelius share price higher this afternoon after the company’s shares opened 1.54% lower at $1.595.

The mid-tier gold mining company reported record full-year FY21 production of 272,109 ounces at an all-in sustaining cost (AISC) of A$1,317/oz.

This compares to the company’s revised guidance of 275,000 to 280,000 ounces at an AISC of A$1,280 to $1,330/oz

Pleasingly, the company’s FY21 production figures represent an 18% increase from FY20 production of 230,426 ounces.

Ramelius advised it had a $228.5 million cash position and an addition $5.4 million of gold bullion on hand as at 30 June 2021.

In addition, the company managed to reduce its debt position to nil. This followed the final debt repayment of $8.1 million at the end of the quarter.

Looking ahead

Ramelius could be poised for more growth in FY22 with gold production forecasted to be between 260,000 and 300,000 ounces.

However, its costs are expected to increase with an FY22 AISC forecast of A$1,425 to A$1,525/oz.

The company is forecasting an exploration expenditure for FY22 of $32.1 million.

What’s happening to the Ramelius share price in 2021?

It’s been a tough year for both the Ramelius share price and the broader ASX gold mining sector.

Ramelius shares are down 6.46% year-to-date despite continuing to make headway in its production and exploration activities.

Top-tier ASX-listed mining shares — from low-cost producer Newcrest Mining Ltd (ASX: NCM) to growth-focused Northern Star Resources Ltd (ASX: NST) — also have negative year-to-date returns.

One of the major catalysts behind the weak performance of gold miners this year is the gold spot price. Gold prices have slumped 4.3% year-to-date from US$1,898 to US$1,816.

The post Ramelius (ASX:RMS) share price lifts on record production appeared first on The Motley Fool Australia.

More reading

• Why Appen, Aventus, HomeCo Daily Needs, & Ramelius are dropping
• ASX 200 up 0.2%: Westpac asset sale, Ramsay increases Spire offer
• The Ramelius (ASX:RMS) share price is on watch today. Here’s why

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3fahzuy

The CV Check Ltd (ASX: CV1) share price is storming ahead today following the release of its fourth quarter results.

At the time of writing, the online integrated screening and verification company’s shares are up 9.68% to 17 cents.

Let’s take a closer look and see how the company performed for the 3 months.

CV Check delivers record growth

Investors appear excited by the company’s latest trading update, sending CV Check shares to a 5-month high.

For the quarter ending 30 June, CV Check achieved group record revenue of $6.4 million, a 262% increase on the prior corresponding period. The strong result was driven by growth in the Australian and New Zealand economy as well as the acquisition of the Bright People Technologies (BPT) business.

Net cash from operating activities during Q4 FY21 came to $585,000, adding to its FY21 total of $1.5 million.

CV Check declared a healthy cash bank balance of $12.9 million with no external financing. During April, $1.3 million was paid to clear BPT’s outstanding debt.

Annual Recurring Revenue (ARR) stood at $13.3 million, compared to $11.1 million at the end of March 2021. This reflects a growth of 19.8% and a record for 12-month booked ARR.

The CV Check platform delivered $5 million in revenue for Q4 FY21, up 104% from this time last year ($2.4 million). B2B integrations with HR information systems and applicant tracking systems contributed $0.7 million. Notably, this represents a massive 420% gain over the prior comparable period.

In addition, the company won new customers during the quarter with several booking their first orders. They included Rheinmetall Defence Australia, Think Childcare, Water NSW, Whitehaven Coal, Winning Appliances Group, among other brands.

What did management say?

CV Check executive chair, Ivan Gustavino commented on the result, saying:

As expected, the quarter under review was a significant period of consolidation for CV1 after the acquisition of BPT. That the business was still able to deliver record revenues for a quarter and for booked 12-month ARR speaks volumes of the calibre of the team. Across both sides of the business, all channels performed strongly: direct sales revenue, revenues booked through integration partners and revenue from the international wholesale sales channel.

CV Check share price summary

It has been a whirlwind 12 months for CV Check shareholders. The company’s shares reached as high as 21 cents in February and then fell to 12 cents a few months after. The CV Check share price is up almost 90% in the past year but is down 10% in 2021.

Based on today’s price, CV Check presides a market capitalisation of roughly $72.9 million and has 428 million shares outstanding.

The post CV Check (ASX:CV1) share price rockets 9% on business update appeared first on The Motley Fool Australia.

More reading

• Why the Resolute Mining (ASX:RSG) share price is crashing 8% today
• Should you buy Mineral Resources (ASX:MIN) shares in July for the dividend yield?
• Oil Search (ASX:OSH) share price struggles despite rising oil price
• Why the Brainchip (ASX:BRN) share price is falling today
• 5 reasons why ASX share investors should be optimistic

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended CV Check Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3j1XXtI